Jump to content

For ALK: "FDA Grants Genentech’s Alecensa® (Alectinib) Accelerated Approval for People with a Specific Type of Lung Cancer "


CindyA

Recommended Posts

  • 3 months later...

Wow it's been a long time since I've been on. I guess that's a good thing. Anyway I've been on crizotinib for about 4 years (maybe a little longer) and it looks like I may be building up the resistance. About 2 years ago I had 5 lesions 1-3mm found in the brain and was treated successfully with gamma knife. Last year in October I had 2 more pop up, again 1-3mm in size and treated with gamma knife. I just had my mri on Monday and they found one lesion about 2 mm in size and planning gamma knife in a few weeks. My question is that my doctor called and wants me to come in and talk about switching to alectinib and I was wondering if anyone else has gone through something similar and how they're tolerating this drug? Also I just want to add that this came as a big surprise to me because of how good I've been doing. I'm 46 years old, very active and go to the gym about 4-5 times a week. I've actually been pressing my doctor about giving me a break from the crizotinib and now this! I know I should be thanking my lucky stars for making it this long and I know they're still very optimistic about the future results but it's just so disappointing some times!

 

PS: To the moderators if this is in the wrong place I apologize and please feel free to move it to where it may get some responses. Thanks!

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use. We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.